吉非替尼在非小细胞肺癌治疗中的疗效分离现象的特点及对策

目的：探讨吉非替尼在治疗非小细胞肺癌过程中的疗效分离现象特点及对策。方法非小细胞肺癌患者96例,采用吉非替尼口服药物治疗,对其治疗过程中出现的疗效分离现象的11例患者进行分析讨论。结果分离现象发生率为11.46%,4例发生肺癌原发病灶转移,2例患者脑转移病灶扩大；5例患者出现部分病灶改变不均。结论非小细胞肺癌患者应用吉非替尼治疗过程中会出现疗效分离现象,生物靶向治疗药物并不完全适用于所有癌症,其发生机制及有效对策还有待进一步研究,需在分子靶向的基础上建立进行分子学的机制研究,进一步制定治疗方案。

Characteristics of efficacy separation of gefitinib in the treatment of non-small cell lung cancer and its countermeasures

Objective To evaluate the characteristics of efficacy separation of gefitinib in the treatment of non-small cell lung cancer and its countermeasures.Methods Patients with non-small cell lung cancer 96 cases, all treated with gefitinib oral medication, efficacy separation of 11 patients were discussed.Results The incidence rate of efficacy separation was 11.46%, 4 cases of primary tumor metastasis of lung cancer, 2 cases of brain metastases in patients with enlarged; 5 cases of partial lesions change occurs unevenly.Conclusion Application of gefitinib non-small cell lung cancer patients with efficacy of the process there will be separate phenomena therapy, biological targeted therapies are not fully applicable to all cancers, its mechanism and effective measures to be further research is required in molecular targeted establish mechanisms to study the molecular basis for further treatment plan.